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Abstract
The human ATP-binding cassette family C member 6 (ABCC6) gene encodes an ABC transporter protein (ABCC6), primarily
expressed in liver and kidney. Mutations in the ABCC6 gene cause pseudoxanthoma elasticum (PXE), an autosomal recessive
connective tissue disease characterized by ectopic mineralization of the elastic fibers. The pathophysiology underlying PXE
is incompletely understood, which can at least partly be explained by the undetermined nature of the ABCC6 substrates as
well as the unknown substrate recognition and binding sites. Several compounds, including anionic glutathione conjugates
(N-ethylmaleimide; NEM-GS) and leukotriene C4 (LTC4) were shown to be modestly transported in vitro; conversely, vitamin
K3 (VK3) was demonstrated not to be transported by ABCC6. To predict the possible substrate binding pockets of the
ABCC6 transporter, we generated a 3D homology model of ABCC6 in both open and closed conformation, qualified for
molecular docking and virtual screening approaches. By docking 10 reported in vitro substrates in our ABCC6 3D homology
models, we were able to predict the substrate binding residues of ABCC6. Further, virtual screening of 4651 metabolites
from the Human Serum Metabolome Database against our open conformation model disclosed possible substrates for
ABCC6, which are mostly lipid and biliary secretion compounds, some of which are found to be involved in mineralization.
Docking of these possible substrates in the closed conformation model also showed high affinity. Virtual screening expands
this possibility to explore more compounds that can interact with ABCC6, and may aid in understanding the mechanisms
leading to PXE.
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Introduction
ABCC6 (also known as Multidrug Resistance Protein-6, MRP6)
is a transporter protein, belonging to the adenosine triphosphate
(ATP)-binding cassette (ABC) family, primarily expressed in liver
and kidney [1]. Perturbance of the ABCC6 transporter due to
mutations in the encoding ABCC6 gene causes pseudoxanthoma
elasticum (PXE), an autosomal recessive connective tissue disor-
der, affecting the skin, eyes and cardiovascular system, due to
progressive mineralization and fragmentation of elastic fibers in
the extracellular matrix [2]. Current evidence suggests PXE to be
a metabolic disease, in which the defective ABCC6 protein fails to
transport one or more metabolites from liver and kidney cells into
the circulation [3,4,5,6]. However, until now only in vitro
substrates of the ABCC6 transporter have been identified, mainly
glutathione conjugates, demonstrating ABCC6 to be an organic
anion transporter [6,7,8]. Next to the speculation on the main
physiological substrates, no structural data on possible substrate
recognition and binding sites of ABCC6 are presently available.
As currently no high resolution X-ray crystallographic structure
for ABCC6 is available, 3D homology modeling may be an
alternative to gain insights into potential substrate binding sites
and the mechanisms of substrate interaction with the protein [9].
A 3D configuration of a prokaryotic ABCC6 protein was
successfully modeled using the X-ray structure of the Staphylo-
coccus aureus Sav1866 export pump [10]. Fulop et al (2009) [11]
used this model as a template to build an outward-facing
conformation (that corresponds to the ATP-bound or closed
conformation state) 3D homology model for human ABCC6 and
have used this model and the distribution of PXE-causing
mutations to demonstrate the relevance of the transmission
interfaces as well as the ABC-ABC domain contacts for the
function of the transporter. Varadi et al (2011) [12] were also able
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to build an ATP-free/wide open inward facing confirmation of
this 3D model (http://www.enzim.hu/,varadi/ABCC6/).
In this study, we have first generated an ABCC6 homology
model in open conformation, and applied molecular docking of
known in vitro substrates of ABCC6, to evaluate if we could
predict potential sites responsible for protein-substrate interaction.
Based on the prediction of binding pockets in the ABCC6
transporter, we carried out a virtual screening in the open
conformation ABCC6 model using the Human Serum Metabo-
lome Database (HSMD) against these substrate binding sites of
ABCC6, to generate a list of potential substrate molecules. In the
second phase, we have generated a closed conformation homology
model of ABCC6 to evaluate the reproducibility of the open
conformation docking results. The compounds in this list with the
highest binding energy are discussed on their potential role in PXE
pathophysiology.
Materials and Methods
Homology modeling of ABCC6
The primary sequence of the human ABCC6 protein was
retrieved from the SwissProt Protein database (UniProt Accession:
O95255) which has a sequence length of 1503 amino acids. In
order to find suitable template(s) for the ABCC6 protein, PSI-
BLAST against all existing molecules in the Protein Data Bank
(PDB) was performed [13], which revealed highest homology of
ABCC6 with P-glycoprotein (P-gp, mouse ABCB1 transporter).
Compared to P-gp, ABCC1 has a higher homology with ABCC6,
but no PDB file of ABCC1 is listed in the PDB database. P-gp was
therefore used as a template to generate an open conformation
ABCC6 3D homology model. To generate the open conformation
structure, initially four models which include amino acid residues
302 to 1503 of ABCC6 were generated using three Metaservers
including I-TASSER [14] Genesilico [15] and Pcons [16], and the
MODELLER v9.9 program [17]. Models obtained from I-
TASSER, Genesilico, Pcons and MODELLER were then used
again as templates to build a final model of ABCC6 using
MODELLER 9.9. Secondary structure elements were revealed by
Genesilico Metaserver. The loop regions of the final model were
rebuilt using Modloop [18], and the energy minimization of the
resulting final model was performed using the YASARA energy
minimization server [19].
To meet the observation of a higher homology between ABCC6
and ABCC1 compared to P-gp, we generated a second homology
model with ABCC1 as a template. Because of its absence in the
PDB database, the template was based on the only available
ABCC1 model reported by DeGorter et al. (2008), which is only in
a closed conformation [20]. Because a 3D homology model always
follows the spatial arrangement of the template, we could thus only
generate a closed conformation ABCC6 model based on the
ABCC1 template. The MODELLER v9.9 program and the
template counterparts from 302–856 and 943–1503 were used to
generate this closed conformation 3D homology model. In
addition, a full length 3D structure of ABCC6 was generated
using MODELLER v9.9 containing all 1503 amino acid residues
with P-gp as a template.
Model validation
The stereo-chemical quality of the final models were evaluated
using three different servers (ERRAT [21], Rampage [22] and
ProQ [23]), which are used to determine the statistical significance
of a protein 3D model considering spatial position of amino-acids
and overall stability of the structure. Usually more than 90%
accuracy is expected for the validity of a model. Furthermore,
template-target superposition based on structural alignment has
been used in SuperPose [24] to understand the coverage between
template and target-protein, and the reliability of the model.
Topology and intrinsically disordered region prediction
The membrane topology of the open conformation ABCC6
protein was predicted using software from the PONGO server
[25]. It uses four selected and high scoring predictors - MEMSAT,
TMHMM2, PRODIV and ENSEMBLE 1.0, and the predicted
result can be displayed in a graphical view. As TMHMM [26] has
been considered the best transmembrane prediction method, we
have used the TMHMM server (http://www.cbs.dtu.dk/services/
TMHMM/) individually to assess the probability of the trans-
membrane domain position in the ABCC6 sequence (302–1503).
Furthermore, the ABCC6 amino acid sequence (302–1503) was
divided into four segments and submitted to the MetaDisorder
server [27], a meta-server for the prediction of the intrinsically
disordered region. Exclusion of these disordered regions was
considered during generation of our ABCC6 models.
Electrostatic charge distribution
Electrostatic potential surface (EPS) of both the open and closed
conformation ABCC6 modeled protein including its substrate
binding sites was calculated using PBEQ solver (http://www.
charmm-gui.org/?doc = input/pbeqsolver) and resulted outputs
(3D structure with surface potential scale of 210 Kcal/mol to +
10 Kcal/mol) were displayed in PyMOL (http://www.pymol.org).
Ligand molecules selection
Initially, 8 previously reported in vitro substrates (Table S1)
were designed and validated to use as reference ligands to perform
molecular docking. Ligand coordinates (2D structure; Figure S1)
were obtained from the DrugBank [28], PubChem Compound
database (http://pubchem.ncbi.nlm.nih.gov/) and ZINC database
[29]. Second, vitamin K1 (VK1) and vitamin K2 (VK2) were
evaluated as ligands, as well as vitamin K3 (VK3). The latter was
used as a negative control, as it has been previously shown not to
be transported by ABCC6 [30]. Third, after delineation of
predicted binding site(s), all 4651 metabolites listed in the Human
Serum Metabolome Database (HSMD; http://www.
serummetabolome.ca/scripts/hmdbDownload.cgi) were used to
dock our ABCC6 open conformation 3D homology model. The
substrate molecules with no available coordinates were drawn and
converted into 3D structure, and generation of mol-files was
carried out using the ACD/ChemSketch software [31]. Energy
minimization of these compounds was then performed using the
United Force field (UFF) program [32].
Molecular docking approach for the identification of
substrate binding sites
To identify the substrate binding sites and possible binding
pattern of 8 reported substrates and three vitamin K isoforms with
the ABCC6 transporter protein, molecular docking was performed
using Autodock 4.2 [33] and Autodock Vina [34]. In this study, a
rigid docking protocol was considered in order to reduce the
computational cost and time in which the receptor was kept rigid
and ligands were allowed to rotate. For blind docking, in order to
remove the bias, the whole protein transmembrane (TM) region
was covered with a grid. The size of the grid box was set to 80 A˚ x
80 A˚ x 80 A˚ (x, y and z) with 0.925 A˚ spacing between the grid
points. To search the best conformation space of the ligand, the
Lamarckian Genetic Algorithm was employed. During the blind
docking process, 100 different conformers were generated for each
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ligand with a population size of 150 individuals. A maximum
number of evaluation was set to 2,500,000 and maximum number
of generation to 27,000, while other parameters were kept as
default.
A refined docking was then carried out in a specific area to
optimize the results, for which the grid box size was also set to
80 A˚680 A˚680 A˚ (x, y and z) whereas the space between grid
points was reduced to 0.55277 A˚. For the docking process, the
number of generation was reduced to 20 conformers for each
ligand with a population size of 250 individuals. Maximum
number of evaluation was set to 25,000,000 while maximum
number of generation was set to 27,000. Other parameters were
used as default. In both the initial blind docking and refined
docking approach, selection of the final pose of ligand bound with
the protein was done by giving priority to the lowest binding-
energy conformation with largest binding-cluster of the total
conformers.
A detailed analysis of residues involved in the interaction
between ligands and protein was conducted using the Discovery
Studio 3.1 Visualizer software (Accelyrs Software Inc., Discovery
Studio Modeling Environment, and Release 3.1.San Diego:
Accelrys Software Inc., 2012).
Manual inspection was employed to investigate the occurrence
of mutations in substrate binding sites (SBS). To identify the
number of naturally found mutations residing in SBS, the amino-
acids involved in SBS were compared to the list of natural variants
in ABCC6 at UniProt (http://www.uniprot.org/uniprot/
O95255#section_features) and the unique mutations annotated
in the Leiden Open Variation Database (LOVD) of the ABCC6
gene (http://www.ncbi.nlm.nih.gov/lovd/home.
php?select_db = ABCC6).
Virtual screening and docking
First, structure based virtual screening against HSMD was
carried out with Autodock Vina (for each compound 10 bound
conformations were generated). During virtual screening the
docking was applied only to the substrate binding sites in the
transmembrane region. For this, the grid box was set to
70 A˚670 A˚660 A˚ with default value of 1.0 A˚ spacing by
Autodock Vina. The grid box was large enough to cover the
whole predicted substrate binding region. Furthermore, Autodock
was used to verify the docking results by re-docking the resulted
compounds, and to analyze the interaction between top scoring
compounds and the ABCC6 protein models.
Results and Discussion
Homology modeling of human ABCC6
To generate a homology model of the ABCC6 protein, we
initially performed a PSI-BLAST search towards the PDB
database against the ABCC6 sequence extracted from UniProt
(AC no: O95255). Generally, identity of $30% between the target
and template sequence is widely accepted for comparative
modeling [35]. However, for membrane transporter proteins
identity of $20–40% is expected to establish a protein model of
sufficient quality [36,37]. We found mouse P-gp (PDB ID: 3G5U,
3G60 and 3G61), and Sav1866 (prokaryotic transport pump) to
have the highest sequence identity and query coverage among all
the proteins available in the PDB database, and chose them as a
template to generate an open conformation ABCC6 homology
model. BLAST result shows that ABCC6 shares a 26% sequence
identity and 57% query coverage with mouse P-glycoprotein, and
27% identity and 58% coverage with Sav1866. Though within the
ABCC transporter family ABCC6 has highest sequence homology
with ABCC1 (44.045%), no PDB file of ABCC1 is listed in the
PDB database. However, De Gorter et al. (2008) published an
ABCC1 closed conformation model [20]; comprehensive literature
mining revealed this to be the only available template which we
used to generate a closed conformation ABCC6 homology model.
ABCC6 shows 43.97% sequence identity and a 90.57% query
coverage with the human ABCC1 model. Generally, native state
or an open conformation state is a more stable form of a protein
and more eligible for substrates to bind. Thus, to investigate
potential substrate binding sites of a protein, use of an open
conformation model is first choice. Conformational change of the
closed conformation model during binding and release of the
substrate is a common phenomenon in ATP-dependent trans-
porters. Moreover, a closed conformation model expected to show
low affinity or a higher binding energy to the substrate compared
to an open conformation model. For these reasons, we selected P-
gp as template in our principle docking ABCC6 open conforma-
tion model. An additional advantage of P-gp is the presence of
complex ligands in inward facing conformation, which can
provide information about the substrate binding sites (SBS) in
ABCC6. It has been previously shown that TMD0 and L0 are
responsible for the membrane localization as N-terminal truncated
ABCC6 mutants missing both transmembrane (TMD0) and
cytoplasmic linker (L0) domains were found to be absent from
the plasma membrane [3]. There is however no evidence of
TMD0 being related to substrate binding. Rather, the reported
experiments indicate that the core region of ABCC6 is more likely
to be involved in substrate recognition and binding. Moreover, as
the counterparts of TMD0 and L0 are unavailable in databases,
those external domains were excluded from the N-terminal region
(1–301 amino acids) of the ABCC6 amino acid sequence.
Contrary, our models contain the recently reported conserved
C-terminal PDZ-like sequence- facilitating protein-protein inter-
actions by acting as scaffold, regulating protein activity, protein
stability, and protein mobility in the membrane - which was found
to be critical for the regulation of trafficking and membrane
localization of ABCC6. Removal of or mutation in this sequence
results in decreased protein expression and increased degradation
of ABCC6 [38]. We also have generated an open conformation
3D homology model including all 1503 amino acid residues by
using P-gp as a template, but failed to overcome the quality
threshold (Figure S2) as discussed below.
To prevent generation of low quality models due to low target-
template sequence identity, we used three different Metaservers (I-
Tasser, GeneSilico, and Pcons) and the MODELLER program,
and generated four initial models for each server and program.
Initially, MODELLER used 3G5U, 3G60 and 3G61 as templates
and generated a good open conformation model. I-TASSER also
resulted in a reliable model with a C-value of 20.31 (the C-value
indicates the confidence score calculated by I-TASSER for the
predicted model and ranges from 25 to 2) and a TM score of 0.67
(the TM score measures the structural similarity between two
structures; a TM score .0.5 indicates a model of correct topology)
(Figure S3). Then, by using these models as templates, the final
open conformation model was generated by using MODELLER
which generate a high quality model with a DOPE score of 2
90805.80 (Figure 1). In PyMOL, two chains (chain A and chain B)
were detected in the ABCC6 structure. Chain A had been
constructed by the amino acids from 302 to 856 and chain B from
857 to 1503. Furthermore, the loop regions less than 12 residues of
the final model (560–565, 973–979, 1189–1200, 1221–1225) were
remodeled using the ModLoop server, as it is very difficult to
model loops having more than 12 residues [39]. For the closed
conformation model (Figure 1), only MODELLER program
Molecular Docking Simulations of ABCC6 Transporter
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(obtained DOPE score of2131757.60) and the counterparts of the
template were used to generate the model.
Validation of 3D homology models
Validation of the stereo-chemical properties of the final models
was done using three servers: Rampage, Errat and ProQ. Stereo-
chemical quality results for the open conformation ABCC6 model
obtained by Rampage (Figure S4A) shows that 96.6% residues are
in the favored region, 3.0% residues are in the allowed region and
0.4% residues are in the outliner region. In the closed
conformation ABCC6 model, Rampage showed that 92% of the
amino acids residues are plotted in the favored region, 7.1%
residues are in the allowed region and 0.3% residues are in
outliner region (Figure S4B). Third, an open conformation full-
length ABCC6 model (Figure S2A) containing all amino acid
residues (thus including the disordered region) did not pass the
quality threshold as only 77.5% of amino acid residues were
plotted in the favored region (Figure S2B). The residues in the
outliner or disallowed region belong to either the disordered
region or the NBD domain and are thus less likely to play a role in
Figure 1. Human ABCC6 protein homology models, visualized in PyMOL. A) Ribbon representation of the model in wide open
conformation. B) Ribbon representation of the model in closed conformation. Helix and Sheet regions are shown in red and yellow respectively,
whereas the green color represents the loop regions. Similarly, green spheres represent those amino acid residues that fall into the disallowed region
of the Ramachandran plot.
doi:10.1371/journal.pone.0102779.g001
Figure 2. Docking of ten reference compounds revealed the presence of two substrate binding sites in the ABCC6 open
conformation model. A) Intracellular view of the docked reference molecules showed that all the molecules are clustered in two substrate binding
sites (SBS) of the ABCC6 homology model (indicated by two red dotted circles). In addition, intersections of the reference molecule in the binding
sites revealed the overlap and flexibility of the binding sites. B) Location of SBS in the ABCC6 open conformation structure represented in PyMOL. The
3D structure of ABCC6 is green and the major amino acids involved in SBS are highlighted in red.
doi:10.1371/journal.pone.0102779.g002
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substrate binding. Model validation by the ERRAT web server
(http://nihserver.mbi.ucla.edu/ERRATv2) showed an overall
quality factor of 94.858% and 83.34% in the open and closed
conformation ABCC6 model respectively (Figure S4C, S4D),
where a value above 90% usually indicates a high quality model
[21]. The results from the ProQ server demonstrates a ProQ LG
score of 4.717 and 4.412, and a ProQ MaxSub score of 0.309 and
0.279 in the open and closed conformation model respectively. A
proQ LG score of .0.3 indicates good quality of the model and a
ProQ MaxSub score of .0.1 indicates ‘correct’ [24]. SuperPose
showed the superimposed images of template 3G5U and I-
TASSER-model with the final model of ABCC6 separately (Figure
S5A and S5B respectively). It depicted the 3D alignment of
template and target protein. In SuperPose, we found an identity
and similarity of 21.9% and 38.5% respectively for the 3G5U-
open conformation ABCC6 structural alignment. For open
conformation-ABCC6-I-TASSER, both the identity and similarity
was 79.9%. SuperPose shows 45.1% of identity and 64% of
similarity for the ABCC1-closed conformation ABCC6 model,
and of 21.7% of identity and of 40.7% similarity for the P-gp-
based full-length ABCC6 model. Therefore, both the 3G5U and I-
TASSER-model had good coverage of length and structure, where
the spatial organization of the target protein is much closer to the
I-TASSER-model. In addition, sequence alignment of template
and open conformation ABCC6 (Figure S6), shows the closeness
between these two models. Thus, overall quality validation
revealed that the open conformation ABCC6 homology model
generated using P-gp as a template is the most accurate model to
perform molecular docking analysis.
Analysis of topology and secondary structure, and
prediction of protein disordered region
According to previous studies, the membrane topology model of
human ABCC6 is composed of 17 transmembrane helices with the
topology arrangement of TMD0-L0-TMD1-ABC1-L-TMD2-
ABC2, two nucleotide-binding domains (NBD1 and NBD2) and
two Walker motifs Walker-A and Walker-B [3]. The TMD0 is
formed by five membrane spanning helices whereas the TMD1
and TMD2 domains are formed by 6 membrane helices each
[3,40]. The predicted result found by the PONGO server
(presented only for the open conformation ABCC6 model in
Figure S7) in our study shows a similar and consistent
conformation. This result is also supported by the TMHMM
server result where it showed a plot of posterior probabilities (0 to
1) of inside, outside and TM helix. At the top of the plot (between
1 and 1.2) the N-best predictions are shown. TMHMM showed
two major spots of transmembrane helices from 302–600 and
900–1225 as expected. In TMHMM, the first and second portion
present 6 and 4 membrane helices respectively, while PONGO
predicts 6 membrane helices in both portions.
The intrinsically disordered/unstructured region of a protein is
the region which does not have a well-defined three dimensional
structure and can exhibit a large number of conformations over
time [41]. The region between amino acid residues 856 to 943 in
our study was found to be disordered and less likely to form a
stable structure for the ABCC6 protein (Figure S8). Indeed, the
model including this region did not fulfil the quality criteria. This
disordered region was removed from the ABCC6 sequence in the
open and closed confirmation model, and thus ignored for model
generation and blind docking analysis.
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Blind docking analysis for the prediction of substrate
binding sites
Since the substrate binding sites of the ABCC6 transporter are
yet to be defined, we used a blind docking approach by using
Autodock tools for the 8 compounds that were reported to be
transported in vitro by ABCC6 as reference substrates to our
models. In addition, because of the suggestion of involvement of
vitamin K in the PXE pathophysiology, we also performed blind
docking for the three known vitamin K isoforms: VK1, VK2 and
VK3. The latter has already been shown not be transported by
ABCC6 and was thus used as a negative control [30].
In the blind docking approach, by using the grid volume that
covers the whole transmembrane region of the protein for the 10
compounds (8 reported substrates, VK1 and VK2) distributed
over the open conformation homology model the potent binding
areas were predicted. Further, a refined docking for specific areas
was carried out to optimize the results. This refined docking
approach resulted in 20 different binding conformations for each
compound. These conformations were clustered together with
RMSD (root mean square deviation) ,4 Au. The lowest binding
energy conformation from the largest cluster was chosen.
From the blind docking and subsequent refined docking, the 10
reference compounds were found to bind in two specific hotspot
areas of the open conformation ABCC6 model, which may
indicate the presence of two substrate binding sites (SBS; Figure 2).
Structure analysis revealed that both chain-A (302–856AA) and
chain-B (857–1503AA) are involved in the conformation of SBS-1
(substantial amino acids: Ser470, Asn474, Gln540, Thr543,
Asn575, Asn578, Lys579, Arg964, Gln1217, Trp1218, Arg1221)
and involved in SBS-2 (substantial amino acids: Glu1176,
Asn1180, Thr1213). Moreover, docking result shows that SBS-1
is formed by TM6, TM9, TM10, TM11, TM12, TM13, TM14
and TM17, whereas SBS-2 is formed by TM6, TM7, TM15,
TM16 and TM17. The interactions of reference compounds and
SBS are enlisted in Table 1.
We noted that some ligands that bind in these predicted binding
sites also partly overlap with each other (Figure 2A and Figure 3),
thus resembling a large flexible cavity instead of two separate
binding pockets. The presence of such a large flexible substrate
binding cavity has been shown for several ABC transporters (e.g.
P-gp, ABCC1) and allows the possibility of a wide range of
substrates [42,43].
On the other hand, refined docking of the 10 reference
compounds shows that all the compounds bind in a specific area of
the closed conformation ABCC6 model. Structure analysis
revealed only Chain-A (302–856AA) to be involved in the
substrate binding site conformation (substantial amino acids are
Ser470, Gln540, Thr543, Asn575, Asn578, Lys579), which
revealed .55% amino acid residues similarity to SBS-1 in the
open conformation ABCC6 homology model. Taking into account
the closed conformation refined docking result, this is suggestive
for ABCC6 to have a single big flexible binding pocket. However,
we need to take into account that the closed conformation model
result may be less reliable and definite conclusion at this point are
therefore not possible.
Remarkably, average docking energy of Autodock and Auto-
dock Vina in both models showed highest binding affinity for
compound BQ-123 followed by teniposide. BQ-123 was seen to
interact with the active site residue Lys579 by forming two
hydrogen bonds with bond distance of 1.73Au and 2.26Au and
single hydrogen bond with residue Gln1217 with bond distance of
1.75Au. Teniposide was found to interact with residue Gln540 by
two hydrogen bonds with bond distance of 2.375Au and 2.166Au
and single hydrogen bond with residue Thr543 with bond distance
of 1.93Au. In contrast, VK3 shows low binding affinity and higher
binding energy (than the average of 10 reference compounds).
Moreover, this binding energy was generated for an outer face site
in the open conformation ABCC6 model (Figure S9). Its low
affinity and lack of specificity for a binding site is consistent with
VK3 not being transported by ABCC6. The final docking result of
the 10 compounds along with corresponding binding energy for
both models is illustrated in Table 1 and the representative
binding mode is shown in Figure 4. Residues involved in
hydrophobic interactions with corresponding substrate molecules
are shown in Table S2.
Furthermore, multiple sequence alignment with the two most
closely related members of the human ABC family, ABCC1 and
ABCC2 shows that most of the residues in the predicted binding
regions from ABCC6 are found to be conserved with those
residues of ABCC1 or ABCC2 that are reported to play significant
role in substrate binding (Figure S10) [44,45,46,47]. Residues such
as Trp1218 contributing in hydrogen bonding and hydrophobic
interactions between ABCC6 and its substrates, was found
conserved. Asn575, Asn578, Lys579, Thr1213 and Arg1221
residues are conserved among ABCC6 paralogs, found in the
substrate binding pockets of other ABC proteins, and have been
described to be efficient for substrate specificity and transport
function [45,47,48,49,50]. As shown in Table S2, the majority of
residues that contribute in the interactions with substrate
molecules are present in TM 9, 10, 11, 16 and 17. This is
consistent with a number of observations suggesting that ABCC1,
ABCB1 and other related ABC proteins possess multiple substrate
binding sites and that the transmembrane domains such as TM9,
10, 11, 16 and 17 play a significant role in substrate recognition
and binding [42,51,52].
Evaluation of the mutations which affect the amino acids
involved in SBS revealed that, among 288 known unique
mutations (www.ncbi.nlm.nih.gov/lovd/), only 16 mutations have
been found to be involved in SBS-1, and 4 mutations have been
found in SBS-2 of the open conformation model (Table 2). This
result may signify that few ABCC6 mutations cause disruption of
substrate binding to ABCC6, but that most disease causing
Figure 3. Extracellular face view of an arrangement of
transmembrane (TM) regions at the proposed binding sites.
Docking poses of substrate BQ-123 (green) and leukotriene C4 (red) into
two different predicted substrate binding sites in the human open
conformation ABCC6 homology model overlap partially with each
other, sharing common residues Lys579 and Gln1217 by forming
hydrogen bonding. The 12 transmembrane domains are numbered
TM6 to TM17 (red).
doi:10.1371/journal.pone.0102779.g003
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mutations of ABCC6 are probably involved in Nucleotide Binding
Domain (NBD) or other portions of the protein that are important
for protein localization, so that it causes the inactivation or mis-
localization of ABCC6. This was recently also suggested by Xue et
al. [38].
Electrostatic Potential Surfaces (EPS)
EPS of the ligand recognition area in the ABC transporters is of
particular interest, since EPS can elucidate the substrate differen-
tiation between these transporters [53]. For this reason, the EPS
value of our models was calculated using the PBEQ solver
program. Analysis of the electrostatic charge distribution in our
models revealed variations in surface electrostatic at different
cavities in the ABCC6 protein (Figure 5). Our study shows that the
predicted substrate binding site(s) of ABCC6 model exhibit an
overall positive (or polar) with neutral (or hydrophobic) and large
negative area (Figure 5). Most of the positively charged residues (in
blue color) were found in the cytoplasmic part of the protein,
whereas mostly neutral (or hydrophobic; in white color) with some
spots of positively and negatively (in red color) charged residues
were found at the transmembrane region of the protein surface.
The presence of hydrophobic pockets with spots of negatively and
positively charged residues indicate the role of these residues in
electrostatic interaction with specific substrates [54]. Moreover,
this also suggest that the negatively charged substrates such as S-
2(2, 4-dinitrophenyl glutathione), Leukotriene (LTC4) and BQ-
123 might interact electrostatically with positively charged residues
within two predicted binding regions whereas the positively
charged and neutral hydrophobic substrates such as Doxorubicin,
Daunorubicin, Etoposide, Teniposide, vitamin K1 and vitamin
K2 might interact electrostatically with negatively charged
residues of the ABCC6 open conformation model. Since the
majority of multidrug transporters transport drugs with a positive
charge, it is reasonable to assume the involvement of negatively
charged intra-membranous acidic residues in substrate binding
[54]. The role of these residues in substrate recognition has already
been reported in number of MDR proteins such as the E.coli
MdfA protein [55] and in murine MRP1, where a single ‘Glu’
residue at the TM15 region was found to have a role not only in
transporting cationic anthracyclines but was also important in
transporting conjugated organic anions, such as LTC4 [56].
Virtual screening of Serum Metabolome Database
The virtual screening of 4,651 compounds from HSMD in the
ABCC6 open conformation model using mean binding energy 2
8.5 Kcal/mol for Autodock Vina and 27.2 Kcal/mol for
Autodock from blind docking as a cut-off threshold value (Table
S1) resulted in the selection of the top 50 compounds (1.075% of
the total compounds in HSMD) (Table 3). Most of the compounds
found in this virtual screening are lipid compounds and biliary
secretions. The compounds in the list can be categorized into the
following five classes: lipids (30 compounds), biliary secretions (10
compounds), aromatic hetero-polycyclic compounds (5 com-
pounds), amino acids, peptides and analogs (3 compounds),
nucleosides, nucleotides and analogs (1 compound), and homoge-
neous non-metal (1 compound). Virtual screening and docking of
these top 50 compounds in the closed conformation model showed
lower affinity (higher binding energy) to the compounds than in
the open conformation model. The binding energy is consistently
higher (for every compound) in closed conformation than the open
Figure 4. Two-dimensional representations of the 10 reference compounds, showing H-bond and hydrophobic interactions within
substrate binding sites of ABCC6 open conformation. (A) BQ-123, (B) Doxorubicin, (C) Daunorubicin, (D) Vitamin K1, (E) vitamin K2, (F) S-2(2, 4-
dinitrophenyl) glutathione, (G) Leukotriene C4, (H) NEM-GS, (I) Teniposide, and (J) Etoposide are shown respectively. Residues involved in Van der
Waals interaction are represented by green disks, residues involved in polar interaction or hydrogen bonding are represented by pink disks and
solvent accessible surfaces of the interacting residues are represented by a blue halo around the residues.
doi:10.1371/journal.pone.0102779.g004
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conformation. The average difference of binding energy (with the
compounds) of open and closed state model ranges from 1.5 Kcal/
mol to 3.0 Kcal/mol, that would be the possible substrate-release
energy due to conformational change of the protein. This explains
the substrate binding in a native or open conformation structure of
ABCC6 and then it goes to the closed state after ATP binding, and
releases the substrate by lowering the binding-affinity.
From the listed 50 compounds, several compounds are involved
in vitamin D metabolism, disturbances of which can play a role in
calcification [57,58]. The highest affinity for SBS-1 with a binding
free energy of 210 Kcal/mol, was found for 25-Hydroxyvitamin
D2 (HMDB01438) in ABCC6 open conformation model. It forms
3 hydrogen bonds with residues Thr543, Gln957, Arg964 with
bond distance of 2.1Au, 1.8Au, and 2.3Au respectively (shown in
Figure 6). Besides vitamin D metabolites, several other compounds
were found to be involved in in calcification and calcification
related mechanisms (Table 3). Several of the listed compounds,
such as HMDB01830, HMDB00760, HMDB00907,
HMDB00121, HMDB00761, HMDB00917, HMDB00946,
HMDB01926, HMDB01562, and HMDB00326, have previously
been reported to be transported by other ABC transporter proteins
[59]. Further in vitro and in vivo validation is necessary to
evaluate whether the actual substrates of ABCC6 are among these
compounds.
Conclusion
The current study provides an insight of the 3D structure and
predicted substrate binding sites of the ABCC6 transporter.
Molecular docking of reference substrates predicted two binding
sites or a large flexible binding pocket of the protein, which
allowed searching novel substrates of ABCC6 by performing
ligand-based virtual screening. We have identified compounds
from HSMD which bind with high affinity to the predicted
substrate binding sites of the ABCC6 protein. The amino-acid
residues which are involved in the predicted binding sites are
conserved among ABC transporters and were also found to reside
in the binding sites of ABCC1 and ABCC2 (Figure S10). Though
Table 2. List of ABCC6 mutations reported in the predicted binding sites of ABCC6 open conformation model.
Substrate Binding Site-1
AA involved Variant Protein Variant type Exon Protein change
Chain A L463 1388T.A L463H Missense 11 p.(Leu463His)
N466 1396A.T N466Y Missense 11 p. (Asn466Tyr)
F568 1703C.T F568S Missense 13 p.(Phe568Ser)
F568 1703T.C F568S Missense 13 p.(Phe568Ser)
L946 2836C.A L946I Missense 22 p.(Leu946Ile)
L953 2868T.A L953H Missense 22 p.(Leu953His)
R964 2891G.C R964P Missense 22 p.(Arg964Pro)
998 998+2delT Splice 8i
998 998+2_998+3delTG Splice 8i
Chain B D1006 3307–1006_3882+1582del Del 23i_25i
D1056 3168C.A D1056E Missense 23 p.(Asp1056Glu)
R1064 3190C.T R1064W Missense 23 p.(Arg1064Trp)
G1203 3608G.A G1203D Missense 25 p.(Gly1203Asp)
R1221 3661C.T R1221C Missense 26 p.(Arg1221Cys)
R1221 3662G.A R1221H Missense 26 p.(Arg1221His)
W1223 3668G.A W1223X Nonsense 26 p.(Trp1223*)
Substrate Binding Site-2
Chain A Q363 1087C.T Q363X Nonsense 9 p.(Gln363*)
Q363 1088_1120del33 Q363_R374del Del 9 p.(Gln363_Arg374)
Q363 1087C.T Q363X Nonsense 9 p.(Gln363*)
Q363 1088_1120del33 Q363_R374del Del 9 p.(Gln363_Arg374)
AA: amino acid; Splice: splice site mutation; Del: deletion.
doi:10.1371/journal.pone.0102779.t002
Figure 5. Electrostatic potential surface of the human ABCC6
model with the predicted substrate binding sites (boxed). (A)
EPS for open conformation ABCC6 model, (B) EPS for closed
conformation ABCC6 model. (C, D) EPD of substrate binding site(s) in
open and closed conformation respectively. Electronegative potential
scale of 210 kcal/mol to +10 kcal/mol is shown. Blue, red and white
colors represent positively, negatively and neutrally charged areas
respectively.
doi:10.1371/journal.pone.0102779.g005
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this can be seen as indirect support of the relevance of our findings,
the main limitations of this study remain that it is based on in silico
modeling and prediction. For the blind docking experiment with
HSMD metabolites, we have so far only considered the 50
compounds with highest binding affinity. We should also consider
the possibility that the substrate of ABCC6 is ranked lower than
the top 50 of these compounds, that more than one of the top 50
compounds can be transported at minimal level by ABCC6 and
that there may be a third substrate binding site for the main
substrates of ABCC6. Further, we cannot exclude that the ABCC6
substrate has no direct relation to mineralization but is an
intermediate in a regulatory process. Nevertheless, the results of
this study provide opportunities to further analyze in vitro and
in vivo compounds which may interact with ABCC6, with
potential insights into the function of this transporter and
subsequently the mechanisms underlying PXE.
Supporting Information
Figure S1 Two dimensional structure of the 8 reported
in vitro substrates and 3 vitamin K isoforms.
(TIF)
Figure S2 Human ABCC6 protein homology model
containing full-length amino acid residues. (A) Ribbon
representation of the model in wide open conformation. Helix and
sheet regions are shown in red and yellow respectively, whereas
the green color represents the loop regions. (B) Ramachandran
plot showing distribution of amino acid residues in favored,
allowed and disallowed region.
(TIF)
Figure S3 TMHMM plot shows the probability of the
presence of TM region in the sequence. It shows the amino
acid-wise probabilities for inside, outside and transmembrane
region of the ABCC6 sequence. Probability ranges from 0 to 1. At
the top of the plot, between 1 to 1.2, the best predictions have been
shown as summary. Figure shows 6 TM regions at the first 300T
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Figure 6. Predicted docking pose of the top scoring com-
pounds from the Human SerumMetabolome Database (HSMD)
in the open conformation ABCC6 homology model. Line
representation (blue) of surrounding amino acids involved in the
interaction with the respective compound (stick representation in green
color). HMDB01438 (25-Hydroxy vitamin D2)-ABCC6 interaction in
substrate binding site of ABCC6 generated a binding free energy of
210 Kcal/mol. Residues such as Thr543, Gln957, Arg964 are involved in
the hydrogen bond interaction while the other surrounding amino acid
residues are involved in hydrophobic interactions.
doi:10.1371/journal.pone.0102779.g006
Molecular Docking Simulations of ABCC6 Transporter
PLOS ONE | www.plosone.org 12 July 2014 | Volume 9 | Issue 7 | e102779
aminoacids, and 4 TM regions from amino acid position 600 to
950.
(TIF)
Figure S4 Stereo-chemical validation of the human
ABCC6 protein models. Ramachandran Plot generated by
the RAMPAGE server shows that- (A) in the open conformation
model 96.7% of residues are plotted in the favored region (dark
cyan color), 3.0% of residues in the allowed region (cyan color) and
0.4% of residues in the outliner region (red dot), (B) in the closed
conformation model 92% of the amino acids residues are plotted
in the favored region, 7.1% residues are in the allowed region and
0.3% residues are in the outliner region. (C, D) ERRAT plot for
the ABCC6 model as predicted by the ERRAT server. ERRAT
showed that the model has an overall quality factor of 94.858% (C)
and 83.345% (D) in the open and closed conformation
respectively.
(TIF)
Figure S5 The SuperPose calculation showing the
superposition of the ABCC6 open conformation protein
model with its initial template 3G5U (A) and the I-
TASSER template (B) individually. The target structure is
colored yellow and the template is in red.
(TIF)
Figure S6 The sequence alignment of four templates
(structure generated from MODELLER, Genesilico,
Pcons, I-TASSER) for open conformation model and
the ABCC6 structure (query) is shown by position. The
core portion (300 to 600 amino-acid positions) of ABCC6 between
two transmembrane bundles was found to be highly conserved
among the templates and target sequence. The probable helix beta
sheet has been indicated by small boxes; the conserved amino
acids are indicated by the red boxes.
(TIF)
Figure S7 Prediction of transmembrane (TM) topology
of the ABCC6 protein model using the PONGO server.
PONGO server (used different programs including MEMSAT,
TMHMM2, PRODIV and ENSEMBLE 1.0) revealed the
presence of 12 alpha-transmembrane domains (shown in red); 6
of them are located in between 302–600 amino acid residues, the
remaining 6 are located in between 945–1225 amino acid residues.
(TIF)
Figure S8 Structural disordered region of ABCC6 as
identified using the MetaDisorder server. The plot shows
the results from a series of predictors including- (a) DISOPRED2
[89], (b) PrDOS [90] (c) IUPred short [91] (d) IUpred long [91] (e)
Pdisorder (SoftBerry Product) (f) DISPROT [92] and GlobPlot
[93]. The region between amino acids 850–950 was found to be
disordered with a Disorder tendency value greater than 0.5.
(TIF)
Figure S9 Docking results shows that vitamin K3 (red)
binds near the transmembrane domain at the outer face
of the transmembrane region of open conformation
model, thus not binding in any of the predicted
substrate binding sites (green).
(TIF)
Figure S10 Multiple sequence alignment of human
ABCC6 (MRP6), ABCC1 (MRP1) and ABCC2 (MRP2)
performed in TCOFFEE (http://tcoffee.crg.cat/apps/
tcoffee/do:regular). The conserved amino acid residues
involved in substrate binding activities by forming hydrogen
bonds are marked by black boxes.
(TIF)
Table S1 List of compounds reported to be transported
in vitro by the human ABCC6 protein. No: Number.
(DOCX)
Table S2 The amino acid residues that constitute and
support substrate binding site-1 and binding site-2 are
shown along with the corresponding transmembrane
(TM) domains and chains in the ABCC6 open confor-
mation model. The interaction of 10 reference compounds with
the two substrate binding sites and the hydrogen bonding and
hydrophobic interactions involved are indicated by symbols.
N = Hydrogen bonding; ??? = Hydrophobic interaction; 1 = BQ-
123; 2 = Teniposide; 3 = Etoposide; 4 = Doxorubicin; 5 = NEM-
GS; 6 = S-2(2, 4-dinitrophenyl) glutathione; 7 = Daunorubicin;
8 = Leukotriene C4; 9 = vitamin K1; 10 = vitamin K2.
(DOC)
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